目的 考察復方藜芍片對大鼠原發(fā)性三叉神經(jīng)痛的治療作用并初步探索相關機制。方法 建立雄性SD大鼠眶下神經(jīng)壓迫術原發(fā)性三叉神經(jīng)痛模型，隨機分為模型組、卡馬西平組及復方藜芍片低、中、高劑量（420、840、1 680 mg/kg）組，ig給藥28 d；定期測定術側(cè)面部機械痛敏閾值（MWT）；ELISA試劑盒檢測血清中腫瘤壞死因子-α（TNF-α）、白細胞介素-1β（IL-1β）水平；q-PCR檢測三叉神經(jīng)節(jié)中TNF-α、IL-1β mRNA表達；Western blotting檢測三叉神經(jīng)節(jié)中降鈣素基因相關肽（CGRP）表達；免疫組化檢測大腦紋狀體中磷酸化p38絲裂原活化蛋白激酶（p-p38 MAPK）表達。結(jié)果 術后當天各組大鼠術側(cè)MWT與術前相比均顯著下降（P＜0.05），大鼠原發(fā)性三叉神經(jīng)痛模型造模成功。復方藜芍片高劑量組MWT值為19.58，與模型組比較MWT值增加36.6%（P＜0.05），復方藜芍片對原發(fā)性三叉神經(jīng)痛模型大鼠的MWT有顯著性改善。與卡馬西平組（14.17）相比，復方藜芍片中、高劑量組大鼠MWT均顯著性上升（P＜0.05）。與模型組相比，復方藜芍片中、高劑量組大鼠血清中TNF-α、IL-1β水平，三叉神經(jīng)節(jié)中TNF-α、IL-1β mRNA、CGRP以及紋狀體中p-p38 MAPK表達均顯著下降（P＜0.05）。結(jié)論 復方藜芍片可對原發(fā)性三叉神經(jīng)痛發(fā)揮治療作用，其機制可能與降低炎癥相關因子以及蛋白的表達有關。

Objective To investigate the therapeutic effect of Compound Lishao Tablets on primary trigeminal neuralgia in rats and explore the related mechanism. Methods Primary trigeminal neuralgia model established by chronic constriction injury of the infraorbital nerve, and then these rats were randomly divided into model group, carbamazepine group, low-dose Compound Lishao Tablets group, middle-dose Compound Lishao Tablets group, high-dose Compound Lishao Tablets group for 28 d gavage administration. The mechanical pain threshold (MWT) of the operated side was measured regularly, the levels of TNF-α and IL-1β in serum were detected by ELISA kit, the expression of TNF-α and IL-1β mRNA in trigeminal ganglion was detected by q-PCR, the expression of calcitonin gene related peptide (CGRP) in trigeminal ganglion was detected by Western blotting, and the expression of phosphorylated p38 mitogen activated protein kinase (p-p38 MAPK) in cerebral striatum was detected by immunohistochemistry. Results On the day after operation, MWT at the operative side of rats in all groups was significantly decreased compared with that before operation (P < 0.05), primary trigeminal neuralgia modeling is successful. The MWT value of Compound Lishao Tablet high-dose group was 19.58, which was increased by 36.6% compared with model group (P < 0.05), and Compound Lishao Tablets significantly improved the MWT value of primary trigeminal neuralgia model rats. Compared with the carbamazepine group (14.17), the MWT of rats in the middle-dose Compound Lishao Tablets group and high-dose Compound Lishao Tablets group significantly increased. Compared to the model group, the expression of TNF-α, IL-1β in serum, the level of TNF-α, IL-1β mRNA, CGRP in trigeminal ganglion and the p-p38 MAPK in striatum are significantly decreasing (P < 0.05) of middle-dose Compound Lishao Tablets group and high-dose Compound Lishao Tablets group. Conclusion Compound Lishao Tablets can exert therapeutic effects on primary trigeminal neuralgia, and its mechanism may be related to reducing the expression of inflammation related factors and proteins.

R285.5

國家級大學生創(chuàng)新創(chuàng)業(yè)訓練計劃項目（202110823024）